Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC3564 in Persistent Allergic Rhinitis
NCT05607446Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQC3564 in allergic rhinitis (AR) (4 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Total Nasal Symptom Score at Day 14. Started Sep 2022; status: terminated.
02
Drugs
TQC3564
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05607446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607446.